Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander Eggermont(University Medical Center Utrecht), B. Guillot(Université de Montpellier), Ragini R. Kudchadkar, Ralf Gutzmer(Medizinische Hochschule Hannover), Michele Maio(University of Siena), Michael P. Brown(South Australia Pathology), Jacob Schachter, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Catherine Barrow, Michal Kiciński(European Organisation for Research and Treatment of Cancer), Thierry Lesimple, Dirk Schadendorf(University of Mannheim), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Friedegund Meier(University of Tübingen), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrey Meshcheryakov(Russian Cancer Research Center NN Blokhin), Inge Marie Svane(University of Copenhagen), Peter Hersey(Royal Prince Alfred Hospital), Caroline Dutriaux(Université Paris-Saclay), Lars Bastholt(Odense University Hospital), Jean‐Jacques Grob, Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Shahneen Sandhu(Peter MacCallum Cancer Centre), Pietro Quaglino(Department of Medical Sciences), Paul Lorigan(University of Manchester), Daniil Stroyakovskiy(Shikoku Cancer Center), Paola Queirolo, Alfons J.M. van den Eertwegh(Amsterdam University Medical Centers), Stéphane Dalle(Mount Sinai Hospital), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alexander C. J. van Akkooi(The University of Sydney), James Larkin(Trinity College Dublin), Gerald P. Linette, Laurent Mortier, Susana Puig(Hospital Clínic de Barcelona), Stefan Suciu(Unknown), Matteo S. Carlino(The University of Sydney), Christian U. Blank(Oncode Institute), Leonel F. Hernandez‐Aya(Washington University in St. Louis), Andrew Haydon(The Alfred Hospital), Caroline Robert(Centre National de la Recherche Scientifique), Alex Menzies(The Netherlands Cancer Institute), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Anna Maria Di Giacomo(University of Siena), Georgina V Long(The University of Sydney), Xinni Song, Victoria Atkinson(Greenslopes Private Hospital), Rutger H.T. Koornstra(Radboud University Nijmegen), Adnan Khattak(Edith Cowan University), Mario Mandalà(University of Perugia)
Cited by 388
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k